Vyndaqel® (tafamidis meglumine)
| Full Name | Vyndaqel® (tafamidis meglumine) |
| Drug | Vyndaqel |
| Manufacturer | Pfizer |
| Route of Administration | Oral |
| Site of Care | Home |
| Approved Indication | The treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization |
| Disease | Hereditary ATTR amyloidosis (hATTR) – Cardiomyopathy (CM); Wild type transthyretin amyloid cardiomyopathy (wtATTR-CM) |
| Therapeutic Area | Cardiology |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-930-2043 |
| Fax Number | 877-684-3116 |
| Product Website | vyndamax.pfizerpro.com |
| Patient Resources | Amyloidosis Research Consortium |